

研究成果の刊行に関する一覧表

<ガイドライン>

- ・十二指腸癌診療ガイドライン第1版
- ・陰茎癌診療ガイドライン第1版
- ・後腹膜肉腫診療ガイドライン第1版
- ・成人・小児進行固形がんにおける臓器横断的ゲノム診療のガイドライン第3版
- ・GIST診療ガイドライン2022年版（第4版）
- ・脳腫瘍診療ガイドライン2022年版（小児脳腫瘍編）
- ・頭頸部癌診療ガイドライン2022年版（第4版）

<書籍>

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
緒方貴次、 成田有季 哉、 <u>室 圭</u>	MSI-high固形癌に対する免疫チェックポイント阻害薬治療と当院におけるMSI検査体制		臨床外科 第75巻 第8号	医学書院		2020	958- 966
<u>室 圭</u>	Lower G.I./Colon and Rectum Cancer 大腸癌 大腸癌における各種希少遺伝子異常の診断と治療		癌と化学療法 Vo 1.47 第11号	癌と化学療法社		2020	1557- 1558
<u>室 圭</u>	消化器癌に対する免疫療法の現状と展望		消化器疾患最新の治療2021-2022	南江堂		2021	10-14
本間義崇、 堀松高博、 成田有季 哉、 <u>室 圭</u>	総論 [2] 治療「薬物療法」 各論 薬物療法CQ1-4	十二指腸癌診療ガイドライン作成委員会	十二指腸癌診療ガイドライン 2021年版	金原出版	東京	2021	P. 1- 120
<u>川井 章</u>	全国骨・軟部腫瘍登録	川井 章	肉腫-基礎・臨床の最新知見-	日本臨牀社	東京	2020	35-42
<u>川井 章</u>	希少がん	川井 章	希少がん-がん診療の新たな課題-	日本臨牀社	東京	2021	7-16
<u>杉山 一彦</u>	悪性脳腫瘍治療に必要な分子標的療法の理解のために	杉山 一彦, 橋本直哉	悪性脳腫瘍のすべて Neuro-oncologyの教科書	メディカ出版	大阪	2020	10-20
山口 隆大, <u>神波 大己</u>	陰茎部分切除術	高橋 悟	Urologic Surgery Next 8: 陰茎・陰囊・アンドロロジーの手術	Medical View 社	東京都	2021	2-8
山口隆大, <u>神波大己</u>	陰茎部分切除術	高橋悟	Urologic Surgery Next 8: 陰茎・陰囊・アンドロロジーの手術	Medical View 社	東京都	2021	2-8
<u>西田 佳弘</u>	整形外科疾患 骨・軟部腫瘍 (悪性)	福井次矢/高木誠/小室一成	今日の治療指針 2020	医学書院	東京	2020	1179- 1180

<u>西田佳弘</u>	8. 骨軟部腫瘍	池田 浩／高平尚伸	PT・OTの整形外科学	文光堂	東京	2022	123-143
<u>西田佳弘</u>	I肩関節 上腕骨近位骨軟部腫瘍に対する切除と人工骨頭置換/リパース型人工肩関節置換術	今井晋二	OS NEXUS 上肢の人工関節手術	メジカルビュー社	東京	2023	15-22
<u>西田佳弘</u>	II腫瘍による切断 下肢の切断術の実際	田仲康仁、富村奈津子	四肢切断術のすべて	メジカルビュー社	東京	2023	147-157
<u>小田義直</u> (分担執筆)	悪性軟部腫瘍取り扱い規約 第4版	日本頭消え編	病理診断	金原出版株式会社		2023	21-92
<u>本間明宏</u>		日本頭頸部癌学会	頭頸部癌診療ガイドライン2022年版	金原出版株式会社	東京	2022	1-227

< 論文 >

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Yoshino T, Pentheroudakis G, <u>Kodera Y</u> (著者 19名中15番目) et al JSCO/ESMO/ASCO/ JSMO/ TOS	International expert consensus recommendations for tumor-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions.	Ann Oncol	31(7)	861-872	2020
Sassa N, Yokoyama Y, <u>Kodera Y</u> (著者9名中8番目) , et al.	Clinical characteristics and surgical outcomes of retroperitoneal tumors: a comprehensive data collection from multiple departments.	Int J Clin Oncol	25(5)	929-936	2020
Ishii K, Yokoyama Y, <u>Kodera Y</u> (著者9名中6番目) , et al.	Characteristics of primary and repeated recurrent retroperitoneal liposarcoma: outcomes after aggressive surgeries at a single institution.	Jpn J Clin Oncol	50 (12)	1412-1418	2020
Mizuno K, Ito T, <u>Kodera Y</u> (著者23名中16番目) , et al.	Real world data of injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies.	J Gastroenterol	55(6)	653-661	2020
Kobayashi D, Mochizuki Y, <u>Kodera Y</u> (著者9名中9番目) , et al.	Phase II multi-institutional prospective trial of nab-paclitaxel as second-line chemotherapy for advanced gastric cancer refractory to fluoropyrimidine with modified dose reduction criteria (CCOG1303).	Int J Clin Oncol	25 (10)	1793-1799.	2020

Kanda M, Koike M, Kodera Y (著者11名中11番目), et al.	An open-label single-arm phase II study of treatment with neoadjuvant S-1 plus cisplatin for clinical stage III squamous cell carcinoma of the esophagus.	Oncologist	25 (11)	e1650 -e1654	2020
Burasakarn P, Higuchi R, Kodera Y (著者19名中19番目)	Limited resection vs. pancreaticoduodenectomy for primary duodenal adenocarcinoma: a systematic review and meta-analysis.	Int J Clin Oncol	26(3)	450-460	2021
Japanese Gastric Cancer Association (corresponding author: Y. Kodera).	Japanese gastric cancer treatment guidelines 2018 (5 th edition).	Gastric Cancer	24(1)	1-21	2021
Nakayama G, Takano N, Kodera Y (著者30名中30番目), et al.	Randomised phase II trial of capecitabine plus oxaliplatin with continuous versus intermitted use of oxaliplatin as adjuvant chemotherapy for stage II/III colon cancer (COG-1302 study).	Eur J Cancer	144	61-71	2021
Kanda M, Shimizu D, Kodera Y (著者15名中15番目)	Blockade of CHRN2 signaling with a therapeutic monoclonal antibody attenuates the aggressiveness of gastric cancer cells.	Oncogene	20 (36)	5499-5504	2021
Tanaka H, Kanda M, Kodera Y (著者12名中12番目) .	G-protein subunit gamma-4 expression has potential for detection, prediction and therapeutic targeting in liver metastasis of gastric cancer.	Br J Cancer	125 (2)	220-228	2021
Shimizu D, Taniue K, Matsui Y, Hae no H, Araki H, Miura F, Fukunaga M, Shiraishi K, Miyamoto Y, Tsukamoto S, Komine A, Kobayashi Y, Kitagawa A, Yoshikawa Y, Sato K, Saito T, Ito S, Masuda T, Niida A, Suzuki M, Baba H, Ito T, Akimitsu N, Kodera Y , Mimori K.	Pan-cancer methylome analysis for cancer diagnosis and classification of cancer cell of origin	Cancer Gene Therapy	29(5)	428-436	2022
Miwa T, Yamada S, Shibuya K, Hirano K, Takami H, Watanabe T, Hayashi M, Yoshioka I, Kodera Y , Fujii T	Clip-guided local duodenectomy for safe and minimal local resection of nonampullary duodenal neoplasms	BMC Surg	22(1)	328 (1-7)	2022
Hasegawa H, Shitara K, Kodera Y (著者13名中13番目) .	A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer	Gastric Cancer	25(3)	619-628	2022
Takeji Y, Yoshida K, Kodera Y (著者18名中3番目), et al.	Three-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric cancer: JACCRO GC07.	Gastric Cancer	25(1)	188-196	2022

Nakata Y, Kageyama S, <u>Kodera Y</u> (著者45名中31番目), et al.	Prognostic significance of NY-ESO-1 antigen and PIGR expression in esophageal tumors of CHP-NY-ESO-1-vaccinated patients as a djuvant therapy	Cancer Immunol	71 (11)	2743-2755	2022
Nakagawa K, Sho M, <u>Kodera Y</u> (著者17名中17番目), et al.	Surgical results of non-ampullary duodenal cancer: a nationwide survey in Japan.	J Gastroenterol	57(2)	70-81	2022
横山幸浩、砂川真輝、栗本景介、江畑智希、 <u>小寺泰弘</u>	後腹膜肉腫診療ガイドラインの要点と今後の展望	臨床外科	77(9)	1108-1112	2022
Kanda M, Terashima M, Kinoshita T, Yabusaki H, Tokunaga M, <u>Kodera Y</u> .	A multi-institutional study to evaluate the feasibility of next-generation sequencing and genomic analysis using formalin-fixed, paraffin-embedded biopsies of gastric cancer	Gastric Cancer	26(1)	108-115	2023
Nakamura M, Okamura Y, Ohshima K, Sugiura T, Ashida R, Ohgi K, Bando E, Fujiya K, Shiomi A, Kagawa H, Imamura T, Nakayama G, <u>Kodera Y</u> , Uesaka K, Ohike N, Norose T, Sasaki K, Sugino T, Ohnami S, Nagashima T, Urakami K, Akiyama Y, Yamaguchi K.	Molecular genetic positioning of small intestine and papilla of Vater carcinomas including clinicopathological classification.	Cancer Medicine		in press	2023
Narita Y, Kadowaki S, <u>Muro K</u>	Immune checkpoint inhibitor plus anti-HER2 therapy: a new standard for HER2-positive oesophagogastric cancer?	Lancet Oncol	21(6)	741-743	2020
Masuishi T, Nakajima TE, Yamazaki K, Hironaka S, Kudo C, Yoshimura K, <u>Muro K</u>	WJOG10517G: a multicenter Phase II study of mFOLFOX6 in gastric cancer patients with severe peritoneal metastases.	Future Oncol	16 (20)	1417-1424	2020
Murono K, Nozawa H, Nagata H, Ishimaru K, Sonoda H, Emoto S, Kaneko M, Sasaki K, Otani K, Kawai K, <u>Muro K</u> , Ishihara S	Efficacy of intraperitoneally administered paclitaxel for colorectal cancer with peritoneal metastases.	Int J Colorectal Dis	35 (10)	1945-1949	2020
Nakazawa T, Narita Y, Kumanishi R, Ogata T, Matsubara Y, Nozawa K, Kato K, Honda K, Masuishi T, Bando H, Kadowaki S, Ando M, Hara K, Tajika M, <u>Muro K</u>	Second-line chemotherapy for previously treated metastatic small bowel adenocarcinoma. A retrospective analysis.	Anticancer Res	41 (10)	5147-5155	2021
Fakih MG, Kopetz S, Kuboki Y, Kim TW, Munster PN, Krauss JC, Falchook GS, Han SW, Heinemann V, <u>Muro K</u> , Strickler JH, Hong DS, Denlinger CS, Giotto G, Lee MA, Henary H, Tran Q, Park JK, Ngarmchamnanrith G, Prene H, Price TJ	Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100) a prespecified analysis of a single-arm, phase 2 trial.	Lancet Oncol	23 (1)	115-124	2022

Nakagawa K, Sho M, Fujishiro M, Kakushima N, Horimatsu T, Okada KI, Iguchi M, Uraoka T, Kato M, Yamamoto Y, Aoyama T, Akahori T, Eguchi H, Kanaji S, Kanetaka K, Kuroda S, Nagakawa Y, Nunobe S, Higuchi R, Fujii T, Yamashita H, Yamada S, Narita Y, Honma Y, Muro K , Ushiku T, Ejima Y, Yamaue H, Kodera Y	Clinical practice guidelines for duodenal cancer 2021	J Gastroenterology	57 (12)	927-941	2022
Ogata T, Fujita Y, Muro K	Dramatic Response to Trastuzumab Deruxtecan Rechallenge in a Patient with HER2-Positive Gastric Cancer. A Case Report.	Am J Case Rep	PMID : 35241641 PMCID : PMC8902806 DOI : 10.12659/AJR.935600		2022
Demetri GD, Antonescu CR, Bjerkeheggen B, Kawai A , et al.	Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network.	Annals of Oncology: official journal of the European Society for Medical Oncology.	11	1506-1517	2020
Endo M, Takahashi S, Araki N, Kawai A , et al.	Time lapse analysis of tumor response in patients with soft tissue sarcoma treated with trabectedin: A pooled analysis of two phase II clinical trials.	Cancer Medicine.	11	3656-3667	2020
Kawai A , Higashi T, Shibata T, Yoshida A, et al.	Rare cancers in Japan: definition, clinical features and future perspectives.	Japanese Journal of Clinical Oncology.	50(9)	970-5	2020
Tap WD, Wagner AJ, Kawai A , et al.	Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial.	JAMA	323 (13)	1266-1276	2020
Yoshida A, Arai Y, Kawai A , et al.	Expanding the clinicopathologic and molecular spectrum of BCOR-associated sarcomas in adults.	Histopathology.	76(4)	509-520	2020

Kawai A , Naka N, Shimomura A, Takahashi S, Kitano S, Imura Y, Yonemori K, Nakatani F, Iwata S, Kobayashi E, Outani H, Tamiya H, Naito Y, Yamamoto N, Doi T.	Efficacy and safety of TAS-115, a novel oral multi-kinase inhibitor, in osteosarcoma: an expansion cohort of a phase I study	Invest New Drugs.	39(6)	1559-1567.2021	2021
Iwata S, Kawai A , Ueda T, Ishii T; Japanese Musculoskeletal Oncology Group (JMOG).	Symptomatic Venous Thromboembolism in Patients with Malignant Bone and Soft Tissue Tumors: A Prospective Multicenter Cohort Study.	Ann Surg Oncol.	28(7)	3919-3927	2021
Stacchiotti S, Frezza AM, Blay JY, Kawai A , et al	Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities.	Cancer.	127(16)	2934-2942.2021	2021
Strauss SJ, Frezza AM, Kawai A , et al.	Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up.	Ann Oncol.	32(12)	1520-1536.	2021
Gronchi A, Miah AB, Kawai A , et al.	Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up.	Ann Oncol.	32(11)	1348-1365.2021	2021
Kawai A	The Shape of Tumor Treatment in this Country.	Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association.	27(3)	511-513	2022
Kawai A , Iwata S, et al.	Japanese Orthopaedic Association (JOA) clinical practice guidelines on the management of soft tissue tumors 2020 - Secondary publication.	Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association.	27(3)	533-550	2022
Kawai A , Narahara H, Kobayashi E, et al.	Safety and effectiveness of eribulin in Japanese patients with soft tissue sarcoma including rare subtypes: a post-marketing observational study.	BMC cancer	22(1)	528	2022
Morii T, Anazawa U, Sato C, Iwata S, et al.	Dedifferentiated liposarcoma in the extremity and trunk wall: A multi-institutional study of 132 cases by the Japanese Musculoskeletal Oncology Group (JMOG).	Eur J Surg Oncol.	(22)00631-X	S0748-7983	2022
Takami H, Sugiyama K , et al.; Intracranial Germ Cell Tumor Genome Analysis Consortium (the iGCT Consortium).	Intratumoural immune cell landscape in germinoma reveals multipotent lineages and exhibits prognostic significance.	Neuropathol Appl Neurobiol.	46	111-124	2020

Takeishi Y, <u>Sugiyama K</u> , et al.	Advantage of high b value diffusion-weighted imaging for differentiation of common pediatric brain tumors in posterior fossa.	Eur J Radiol.		Epub 2020 May 5	2020
Tsuyuguchi S, <u>Sugiyama K</u> , et al.	Primary and Recurrent Growing Teratoma Syndrome in Central Nervous System Nongerminomatous Germ Cell Tumors: Case Series and Review of the Literature.	World Neurosurg.	134	e360-e371	2020
Takayasu T, <u>Sugiyama K</u> , et al.	Cerebrospinal fluid ctDNA and metabolites are informative biomarkers for the evaluation of CNS germ cell tumors.	Sci Rep.	10	14326	2020
Aoki T, Kagawa N, <u>Sugiyama K</u> , Wakabayashi T, Arakawa Y, Yamaguchi S, Tanaka S, Ishikawa E, Muragaki Y, Nagane M, Nakada M, Suehiro S, Hata N, Kuroda J, Narita Y, Sonoda Y, Iwadate Y, Natsumeda M, Nakazato Y, Minami H, Hirata Y, Hagihara S, Nishikawa R.	Efficacy and safety of nivolumab in Japanese patients with first recurrence of glioblastoma: an open-label, non-comparative study.	Int J Clin Oncol.	26 (12)	2205-2215	2021
amasaki F, Nishibuchi I, Karakawa S, Kaichi Y, Kolakshyapati M, Takano M, Yonezawa U, Imano N, Taguchi A, Shimomura M, Taniguchi M, Onishi S, Okada S, Awai K, <u>Sugiyama K</u> , Nagata Y.	T2-FLAIR Mismatch Sign and Response to Radiotherapy in Diffuse Intrinsic Pontine Glioma.	Pediatr Neurosurg.	56(1)	1-9	2021
Taguchi A, Kinoshita Y, Amatya VJ, Takayasu T, Takano M, Yonezawa U, Tominaga A, Takeshima Y, <u>Sugiyama K</u> , Yamasaki F.	Intratumoral hemorrhage after endoscopic third ventriculostomy for obstructive hydrocephalus caused by brain tumors.	World Neurosurg.	S1878 - 8750(21)	01673-9	2021
Narita Y, Nagane M, Mishima K, Terui Y, Arakawa Y, Yonezawa H, Asai K, Fukuhara N, <u>Sugiyama K</u> , Shinojima N, Kitagawa J, Aoi A, Nishikawa R.	Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma.	Neuro Oncol.	23(1)	122-133	2021
Takami H, Satomi K, Fukuoka K, Fukushima S, Matsushita Y, Yamasaki K, Nakamura T, Tanaka S, Mukasa A, Saito N, Suzuki T, Yanagisawa T, Nakamura H, <u>Sugiyama K</u> , Tamura K, Maehara T, Nakada M, Nonaka M, Asai A, Yokogami K, Takeshima H, Iuchi T, Kanemura Y, Kobayashi K, Nagane M, Kurozumi K, Yoshimoto K, Matsuda M, Matsumura A, Hirose Y, Tokuyama T, <u>Kumabe T</u> , Narita Y, Shibui S, Nakazato Y, Nishikawa R, Matsutani M, Ichimura K.	Low tumor cell content predicts favorable prognosis in germinoma patients.	Neurooncol	3(1)	vdab110. doi: 10.1093/noajnl/vdab110	2021

Satomi K, Takami H, Fukushima S, Yamashita S, Matsushita Y, Nakazato Y, Suzuki T, Tanaka S, Mukasa A, Saito N, Kanamori M, <u>Kumabe T</u> , Tominaga T, Kobayashi K, Nagane M, Iuchi T, Yoshimoto K, Tamura K, Maehara T, Sakai K, <u>Sugiyama K</u> , Yokogami K, Takeshima H, Nonaka M, Asai A, Ushijima T, Matsutani M, Nishikawa R, Ichimura K.	12p gain is predominantly observed in non-germinomatous germ cell tumors and identifies an unfavorable subgroup of central nervous system germ cell tumors.	Neuro Oncol.		noab246. doi: 10.1093/neuonc/noab246.	2021
Ikeda K, Kolakshyapati M, Takayasu T, Amatya VJ, Takano M, Yonezawa U, Taguchi A, Onishi S, Takeshima Y, <u>Sugiyama K</u> , Yamasaki Y.	Diffusion-weighted imaging-gadolinium enhancement mismatch sign in diffuse midline glioma.	Eur J Radiol.	147:110103	doi: 10.1016/j.ejrad.2021.11010.	2022
Kunitomi C, Harada M, Sanada Y, Kusamoto A, Takai Y, Furui T, Kitagawa Y, Yamada M, Watanabe C, Tsugawa K, Nishiyama H, Hosoi H, Miyachi M, <u>Sugiyama K</u> , Maeda Y, Kawai K, Hamatani T, Fujio K, Suzuki N, Osuga Y.	Impact of the Japan Society of Clinical Oncology Clinical Practice Guidelines 2017 on the practice of fertility preservation in female cancer patients in Japan.	Reproductive Medicine and Biology(RMB).	21(1):e12453.	doi: 10.1002/rmb2.12453.	2022
Tozawa A, Kimura F, Takai Y, Nakajima T, Ushijima K, Kobayashi H, Satoh T, Harada M, Sugimoto K, Saji S, Shimizu C, Akiyama K, Bando H, Kuwahara A, Furui T, Okada H, Kawai K, Shinohara N, Nagao K, Kitajima M, Suenobu S, Soejima T, Miyachi M, Miyoshi Y, Yoneda A, Horie A, Ishida Y, Usui N, Kanda Y, Fujii N, Endo M, Nakayama R, Hoshi M, Yonemoto T, Kiyotani C, Okita N, Baba E, Muto M, Kikuchi I, Morishige KI, Tsugawa K, Nishiyama H, Hosoi H, Tanimoto M, Kawai A, <u>Sugiyama K</u> , Boku N, Yonemura M, Hayashi N, Aoki D, Suzuki N, Osuga Y.	Japan Society of Clinical Oncology Clinical Practice Guidelines 2017 for fertility preservation in childhood, adolescent, and young adult cancer patients: part 2.	nt J Clin Oncol.	27(2)	281-300	2022
Nakamura H, Takami H, Yanagisawa T, Kumabe T, Fujimaki T, Arakawa Y, Karasawa K, Terashima K, Yokoo H, Fukuoka K, Sonoda Y, Sakurada K, Mineharu Y, Soejima T, Fujii M, Shinojima N, Hara J, Yamasaki K, Fujimura J, Yamasaki F, Takahashi M, Suzuki T, Sato I, Nishikawa R, <u>Sugiyama K</u> ; guideline committee in The Japan Society for Neuro-Oncology (JSNO) Task Force on Central Nervous System Germ Cell Tumors.	The Japan Society for Neuro-Oncology Guideline on the Diagnosis and Treatment of Central Nervous System Germ Cell Tumors.	Neuro Oncol.	24(4)	503-515	2022
Nagumo Y, Kojima T, Shiga M, Kojo K, Tanaka K, Kandori S, Kimura T, Kawahara T, Kawai K, Okuyama A, Higashi T, <u>Nishiyama H</u> .	Clinicopathological features of malignant urachal tumor: A hospital-based cancer registry data in Japan.	Int J Urol.	27(2)	157-162	2020

Tanaka K, Kandori S, Nitta S, Chihara I, Kojo K, Nagumo Y, Kimura T, Kojima T, Kawai K, Okuyama A, Higashi T, <u>Nishiyama H.</u>	Characteristics of penile cancer in Japan: An analysis of nationwide hospital-based cancer registry data.	Int J Urol	27(6)	538-542	2020
Nagumo Y, Kawai K, Kojima T, Shiga M, Kojo K, Tanaka K, Kandori S, Kimura T, Kawahara T, Okuyama A, Higashi T, <u>Nishiyama H.</u>	Prognostic significance of non-urothelial carcinoma of bladder: analysis of nationwide hospital-based cancer registry data in Japan	Jpn J Clin Oncol.	50(9)	1068-1075	2020
Kimura T, Kawai K, Kandori S, Nitta S, Kojo K, Nagumo Y, Negoro H, Okuyama A, Higashi T, Kojima T, <u>Nishiyama H.</u>	Impact of centralization in primary retroperitoneal sarcoma treatment: analysis using hospital-based cancer registry data in Japan.	Int J Clin Oncol.	25(9)	1687-1694	2020
Matsumoto H, Shiraishi K, Azuma H, Inoue K, Uemura H, Eto M, Ohyama C, Ogawa O, Kikuchi E, Kitamura H, Shinohara N, Takahashi S, Tsuzuki T, Nakagawa M, Narumi Y, <u>Nishiyama H.</u> , Habuchi T, Hinotsu S, Fujii Y, Fujimoto K, Fujimoto H, Mizowaki T, Matsuyama H.	Clinical Practice Guidelines for Bladder Cancer 2019 update by the Japanese Urological Association: Summary of the revision.	Int J Urol.	27(9)	702-709	2020
Matsumoto H, Shiraishi K, Azuma H, Inoue K, Uemura H, Eto M, Ohyama C, Ogawa O, Kikuchi E, Kitamura H, Shinohara N, Takahashi S, Tsuzuki T, Nakagawa M, Narumi Y, <u>Nishiyama H.</u> , Habuchi T, Hinotsu S, Fujii Y, Fujimoto K, Fujimoto H, Mizowaki T, Matsuyama H.	Clinical Practice Guidelines for Bladder Cancer 2019 edition by the Japanese Urological Association: Revision working position paper.	Int J Urol.	27(5)	362-368	2020
Nagumo Y, Kawai K, Kojima T, Shiga M, Kojo K, Tanaka K, Kandori S, Kimura T, Kawahara T, Okuyama A, Higashi T, <u>Nishiyama H.</u>	Prognostic impact of non-urothelial carcinoma of the upper urinary tract: Analysis of hospital-based cancer registry data in Japan.	Int J Urol.	28(1)	54-60	2021
根来宏光、 <u>西山博之</u>	男性がん患者に対する治療時の避妊と妊孕性温存に関数情報提供の現状と将来像	癌と化学療法	48巻	644 ~ 648	2021
木村友和、 <u>西山博之</u>	陰茎がん	腫瘍内科	28巻	19~25	2021
近藤千紘、 <u>西山博之</u> ほか	【がん薬物療法時の腎障害診療ガイドライン2022版のポイント】がんサバイバーにおける慢性腎臓病のマネジメント	癌と化学療法	49巻	1200-1204	2022
石塚修、 <u>西山博之</u> ほか	ガイドライン・取扱い規約作成における関連学会との連携	日本泌尿器化学雑誌	113巻	S62-S64	2022
井上高光、 <u>西山博之</u>	【Onconeurology】泌尿器科医から見たonconeurology	日本腎臓学会誌	64巻	433-439	2022
山口隆大、 <u>神波大己</u>	泌尿器科診療の最新スタンダード 平成の常識は令和の非常識：陰茎癌	臨床泌尿器科	74巻4号(増刊号)	93-97	2020

Yamaguchi T, <u>Kamba T</u> , et al.	Summary of clinical practice guidelines for penile cancer 2021 by the Japanese Urological Association	Int J Urol	29(8)	780-792	2022
<u>神波大己</u>	HPV 関連腫瘍としての陰茎癌	Monthly Book ENTONI	281 (3)	49-58	2023
<u>神波大己</u>	日本初の陰茎癌診療ガイドライン 2021 年版について	癌と化学療法	50(1)	55-58	2023
松岡歩、 <u>安藤雄一</u>	高齢者のがん薬物療法ガイドラインについて	日本病院薬剤師会雑誌	56巻11号	p1261-1266	2020
Nishiwaki S, <u>Ando Y</u>	COVID-19 pandemic and trends in clinical trials: a multi-region and global perspective.	Front Med (Lausanne)	Dec 24;8	812370	2021
<u>Yuichi Ando</u> , et al.(他に著者 9 名)	A rapid and durable response to larotrectinib in a patient with NTRK fusion-positive secretory carcinoma originating from the external auditory canal.	Int Cancer Conf J.	11(4)	242-246	2022
Takahiro Yamaguchi, <u>Yuichi Ando</u> , Tomomi Kamba, et al.(他に著者 24 名)	Summary of the Clinical Practice Guidelines for Penile Cancer 2021 by the Japanese Urological Association.	Int. J. Urol	29(8)	780-792	2022
近藤千晶、河田健司、 <u>安藤雄一</u>	本邦におけるがん遺伝子パネル検査の実施体制と課題.	胆と膵	43 巻6号	517-522	2022
石田秀行、近谷賢一、母里淑子、百瀬修二、長田久人、山野智基、富田尚裕、秋山泰樹、平田敬治、六車直樹、高山哲治、 <u>西田佳弘</u> 、石川秀樹	家族性大腸腺腫症に合併するデスマイド腫瘍の診断・治療と重症度分類の提案	遺伝性腫瘍	20巻2号	45-58	2020
<u>西田 佳弘</u>	【泌尿器・生殖器がん、希少がん】希少がん デスマイド腫瘍に対する治療方針 日本と世界の診療ガイドラインにもとづいて	腫瘍内科	26巻4号	407-412	2020
<u>西田 佳弘</u>	【肉腫－基礎・臨床の最新知見－】肉腫の組織型別治療と成績 デスマイド型線維腫症	日本臨床	78巻増刊5肉腫	682-686	2020
<u>Yoshihiro Nishida</u> et al,	Limitations and benefits of FDG-PET/CT in NF1 patients with nerve sheath tumors: A cross-sectional/longitudinal study.	Cancer Science	112	1114-1122	2021
<u>Nishida Y</u> , Urakawa H, Nakayama R, Kobayashi E, Ozaki T, Ae K, Matsumoto Y, Tsuchiya H, Goto T, Hiraga H, Naka N, Takahashi S, Ando Y, Ando M, Kuwatsuka Y, Hamada S, Ueda T, Kawai A.	Phase II clinical trial of pazopanib for patients with unresectable or metastatic malignant peripheral nerve sheath tumors.	Int J Cancer.	148 (1)	140-149	2021
<u>西田 佳弘</u>	骨軟部 良性軟部腫瘍・デスマイド型線維腫症の診断・治療指	最新主要文献とガイド	第1版	239-244	2021

	針	ラインでみる整形外科学レビュー 2021-'22			
<u>西田 佳弘</u>	Current Organ Topics 骨・軟部腫瘍 骨軟部に対する薬物療法ー最近の話題ー デスモイドに対するエビデンスに基づいた薬物療法ー抗がん剤、分子標的薬	癌と化学療法	48巻3号	342-345	2021
<u>西田 佳弘</u>	希少がん がん診療の新たな課題 II希少がん疾患各論 10. 骨軟部腫瘍 (11)悪性末梢神経鞘腫瘍	日本臨床	79巻増刊1	511-515	2021
<u>西田 佳弘</u>	巻頭言 希少疾患から学び、得られる診療の底力	日本義肢協会誌	125巻	Page1	2021
<u>Nishida Y</u> , Kawai A.	Surgical treatment for extremity rhabdomyosarcoma: longitudinal national questionnaire survey in Japan.	Jpn J Clin Oncol.	52(4)	362-369	2022
Urakawa H, Nagano A, Machida R, Tanaka K, Kataoka T, Sekino Y, <u>Nishida Y</u> , Takahashi M, Kunisada T, Kawano M, Yoshida Y, Takagi T, Sato K, Hiruma T, Hatano H, Tsukushi S, Sakamoto A, Akisue T, Hiraoka K, Ozaki T.	A randomized phase III trial of denosumab before curettage for giant cell tumor of bone. JCOG1610.	Jpn J Clin Oncol.	52(9)	1021-1028	2022
Kawai A, Araki N, Ae K, Akiyama T, Ozaki T, Kawano H, Kunisada T, Sumi M, Takahashi S, Tanaka K, Tsukushi S, Naka N, <u>Nishida Y</u> , Miyachi M, Yamamoto N, Yoshida A, Yonemoto T, Yoshida M, Iwata S.	Japanese Orthopaedic Association (JOA) clinical practice guidelines on the management of soft tissue tumors 2020 - Secondary publication.	J Orthop Sci.	27(3)	533-550	2022
Yamashita K, Funauchi Y, Hayakawa K, Ae K, Matsumoto S, Ikuta K, <u>Nishida Y</u> , Ueno T, Shimoyama Y, Hiruta N, Machinami R, Kawachi H, Takeuchi K.	S100-negative epithelioid malignant peripheral nerve sheath tumor with possible perineurial differentiation.	Virchows Arch.	480(6)	1269-1275	2022
Kozawa E, <u>Nishida Y</u> , Kawai A, Hayakawa K, Nokitaka S, Kawashima H, Iwata S, Tsuchiya H, Tsukushi S, Takenaka S, Imanishi J, Baba I, Nagano A, Morii T, Shirai T, Shimizu K, Kawano H.	Clinical features and treatment outcomes of dedifferentiated and grade 3 chondrosarcoma: A multi-institutional study.	Cancer Sci.	113(7)	2397-2408	2022
Ito K, <u>Nishida Y</u> , Hamada S, Shimizu K, Sakai T, Ohkawara B, Alman BA, Enomoto A, Ikuta K, Koike H, Zhang J, Ohno K, Imagama S.	Efficacy of auranofin as an inhibitor of desmoid progression.	Sci Rep	12(1)	11918	2022
Takeuchi A, Endo M, Kawai A, <u>Nishida Y</u> , Terauchi R, Matsumine A, Aiba H, Nakamura T, Tandai S, Ozaki T, Hoshi M, Kayano D, Okuda M, Yamamoto N, Hayashi K, Miwa S, Igarashi K,	Randomized placebo-controlled double-blind phase II study of zaltoprofen for patients with diffuse-type and unresectable	Front Oncol	12:900010		2022

Yoshimura K, Nomura A, Murayama T, Tsuchiya H.	localized tenosynovial giant cell tumors: The REALIZE study.				
Sakai T, Nishida Y , Ito K, Ikuta K, Urakawa H, Koike H, Imagama S.	Clinical results of active surveillance for extra-abdominal desmoid-type fibromatosis.	Cancer Med.	12(5)	5245-5254	2022
Tanaka K, Machida R, Kawai A, Nakayama R, Tsukushi S, Asanuma K, Matsumoto Y, Hiraga H, Hiraoka K, Watanuki M, Yonemoto T, Abe S, Katagiri H, Nishida Y , Nagano A, Suehara Y, Kawashima H, Kawano M, Morii T, Hatano H, Toguchida J, Okuma T, Takeyama M, Takenaka S, Akisue T, Furuta T, Emori M, Hiruma T, Outani H, Yamamoto T, Kataoka T, Fukuda H, Ozaki T, Iwamoto Y.	Perioperative Adriamycin plus ifosfamide vs. gemcitabine plus docetaxel for high-risk soft tissue sarcomas: randomised, phase II/III study JCOG1306.	Br J Cancer.	127 (8)	1487-1496	2022
西田佳弘 、小池 宏、生田国大、酒井智久、伊藤 鑑、今釜史郎	【整形外科画像診断・評価の進歩】MRI 骨肉腫の術前化学療法評価における拡散強調画像の有用性	整形外科	73 巻 6 号	601-604	2022
西田佳弘 、酒井智久、生田国大、小池 宏、伊藤 鑑、今釜史郎	薬物療法の適応と限界 1・2 デスモイドに対する薬物治療	日本整形外科学会雑誌	96 巻 7 号	488-493	2022
西田佳弘	骨・軟部腫瘍に対する診療戦略の変遷	日本整形外科学会雑誌	96 巻 10 号	852-860	2022
Sakai T, Okuno Y, Murakami N, Shimoyama Y, Imagama S, Nishida Y . Front Oncol.	Case report: Novel NIPBL-BEND2 fusion gene identified in osteoblastoma-like phosphaturic mesenchymal tumor of the fibula.	Front Oncol.	12:956472.		2023
Morii T, Anazawa U, Sato C, Iwata S, Nakagawa M, Endo M, Nakamura T, Ikuta K, Nishida Y , Nakayama R, Udaka T, Kawamoto T, Kito M, Sato K, Imanishi J, Akiyama T, Kobayashi H, Nagano A, Outani H, Toki S, Nishisho T, Sasa K, Suehara Y, Kawano H, Ueda T, Morioka H.	Dedifferentiated liposarcoma in the extremity and trunk wall: A multi-institutional study of 132 cases by the Japanese Musculoskeletal Oncology Group (JMOG).	Eur J Surg Oncol.	49(2)	353-361	2023
Nakashima Y, Yokoyama Y, Ogawa H, Sakakibara A, Sunagawa M, Nishida Y , Mizuno T, Yamaguchi J, Onoe S, Watanabe N, Kawakatsu S, Igami T, Ebata T.	Which modality is better to diagnose high-grade transformation in retroperitoneal liposarcoma? Comparison of computed tomography, positron emission tomography, and magnetic resonance imaging.	Int J Clin Oncol.	28(3)	482-490	2023
Cortes-Ciriano I, Steele CD, Piculell K, Al-Ibraheemi A, Eulo V, Bui MM, Chatzipli A, Dickson BC, Borchering DC, Feber A, Galor A, Hart J, Jones KB, Jordan JT, Kim RH, Lindsay D, Miller C, Nishida Y , Proszek PZ, Serrano J, Sundby RT, Szymanski JJ, Ullrich NJ, Viskochil D, Wang X, Snuderl M, Park	Genomic patterns of malignant peripheral nerve sheath tumor (MPNST) evolution correlate with clinical outcome and are detectable in cell-free DNA.	Cancer Discov.	13(3)	654-671	2023

PJ, Flanagan AM, Hirbe AC, Pillay N, Miller DT.					
Arima J, Hiramatsu M, Taniguchi K, Kobayashi T, Tsunematsu I, Kagota S, Sakane J, Suzuki Y, Hirota S.	Multiple gastrointestinal stromal tumors caused by a novel germline <i>KIT</i> gene mutation (Asp820Gly): A case report and literature review.	Gastric Cancer	23	760-764	2020
Nishida T, Sakai Y, Takagi M, Ozaka M, Kitagawa Y, Kurokawa Y, Masuzawa T, Naito Y, Kagimura T, Hirota S; members of the STAR ReGISTry Study Group.	Adherence to the guidelines and the pathological diagnosis of high-risk gastrointestinal stromal tumors in the real world.	Gastric Cancer	23	118-125	2020
Saito Y, Takahashi T, Obata Y, Nishida T, Ohkubo S, Nakagawa F, Serada S, Fujimoto M, Ohkawara T, Nishigaki T, Sugase T, Koh M, Ishida T, Tanaka K, Miyazaki Y, Makino T, Kurokawa Y, Nakajima K, Yamasaki M, Hirota S. Naka T, Mori M, Doki Y.	TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours.	Br J Cancer	122	658-667	2020
Yamauchi A, Chinen Y, Chihara T, Ueda M, Ikenaga M, Yamada T, Hirota S.	A case of planar-type gastrointestinal stromal tumor of the transverse colon with perforation.	Clin J Gastroenterol	14(4)	1157-1162	2021
Yuan J, Kihara T, Kimura N, Hashikura Y, Ohkouchi M, Isozaki K, Takahashi T, Nishida T, Ito A, Hirota S.	Differential expression of <i>CADM1</i> in gastrointestinal stromal tumors of different sites and with different gene abnormalities.	Pathol Oncol Res	27	602008	2021
Ishida T, Takahashi T, Kurokawa Y, Nishida T, Hirota S. , Serada S, Fujimoto M, Naka T, Teranishi R, Saito T, Yamashita K, Tanaka K, Yamamoto K, Makino T, Yamasaki M, Nakajima K, Eguchi H, Doki Y.	Targeted therapy for drug-tolerant persister cells after imatinib treatment for gastrointestinal stromal tumours.	Br J Cancer.	125	1511-1522	2021
Ogawa S, Nishihara M, Nakanishi T, Maeda T, Hirota S.	A rare case of extraluminally pedunculated gastrointestinal stromal tumor with postoperative metastasis to pancreas.	J Surg Case Rep.	2021	rjab422	2021
Kihara T, Yuan J, Watabe T, Kitajima K, Kimura N, Ohkouchi M, Hashikura Y, Ohkubo S, Takahashi T, Hirota S	Kihara T, Yuan J, Watabe T, Kitajima K, Kimura N, Ohkouchi M, Hashikura Y, Ohkubo S, Takahashi T, Hirota S	Exp Mol Pathol.	123	104692	2021
Cho H, Nishida T, Takahashi T, Masuzawa T, Hirota S.	Impact of the <i>KIT</i> / <i>PDGFRA</i> genotype on prognosis in imatinib-naïve Japanese patients with gastrointestinal stromal tumor.	Ann Gastroenterol Surg.	6	241-248	2021
Yuan J, Kihara T, Kimura N, Yamasaki T, Yoshida M, Isozaki K, Ito A, Hirota S.	<i>CADM1</i> promotes adhesion to vascular endothelial cells and transendothelial migration in cultured GIST cells.	Oncol Lett.	23	86	2022
Ushimaru Y, Takahashi T, Nakajima K, Teranishi R, Nishida T, Hirota S. Motoori M, Omori T, Kawabata R, Nishikawa K, Saito T, Yamashita K,	Real-world data on the efficacy and safety of adjuvant chemotherapy in Japanese patients with a high-risk of gastrointestinal stromal tumor	Int J Clin Oncol.	27	921-929	2022

Tanaka K, Makino T, Yamamoto K, Kurokawa Y, Eguchi H, Doki Y.	recurrence.				
Teranishi R, Takahashi T, Nishida T, Hirota S , Kurokawa Y, Saito T, Yamamoto K, Yamashita K, Tanaka K, Makino T, Motoori M, Omori T, Nakajima K, Eguchi H, Doki Y.	Efficacy and safety of Regorafenib in Japanese patients with advanced gastrointestinal stromal tumors.	Int J Clin Oncol.	27	1164-1172	2022
Nishida T, Sato S, Ozaka M, Nakahara Y, Komatsu Y, Kondo M, Cho H, Hirota S , Kagimura T, Kurokawa Y, Kitagawa Y; STAR ReGISTry Investigators.	Long-term adjuvant therapy for high-risk gastrointestinal stromal tumors in the real world.	Gastric Cancer.	25	956-965	2022
Fukada A, Takahashi T, Kurokawa Y, Asaoka T, Teranishi R, Saito T, Yamamoto K, Yamashita K, Tanaka K, Makino T, Nakajima K, Umeda D, Morii E, Hirota S , Eguchi H, Doki Y.	Laparoscopic resection for recurrent gastrointestinal stromal tumors and paraganglioma in a patient with Carney-Stratakis syndrome: A case report.	Asian J Endosc Surg.	16	90-94	2023
Kanda T, Naito T, Wakai A, Iwafuchi Y, Hirota S , Ajioka Y.	Late recurrence of low-risk gastrointestinal stromal tumor of jejunum diagnosed 30 years after tumor resection: A case report and literature review.	Oncol Lett.	25	50	2023
Sasaki K, Kanda T, Matsumoto Y, Ishikawa T, Hirota S , Saijo Y.	Sunitinib therapy for imatinib-resistant and/or intolerant gastrointestinal stromal tumors: comparison of safety and efficacy between standard and reduced dosage regimens.	Jpn J Clin Oncol.	53	297-303	2023
Teranishi R, Takahashi T, Obata Y, Nishida T, Ohkubo S, Kazuno H, Saito Y, Serada S, Fujimoto M, Kurokawa Y, Saito T, Yamamoto K, Yamashita K, Tanaka K, Makino T, Nakajima K, Hirota S, Naka T, Eguchi H, Doki Y.	Combination of pimitespib (TAS-116) with sunitinib is an effective therapy for imatinib-resistant gastrointestinal stromal tumors.	Int J Cancer.	152	2580-2593	2023
Sano D, Kihara T, Yuan J, Kimura N, Ohkouchi M, Hashikura Y, Ohkubo S, Hirota S .	Characterization of cell line with dedifferentiated GIST-like features established from cecal GIST of familial GIST model mice.	Pathol Int.			2023, in press
Teranishi R, Takahashi T, Nishida T, Kurokawa Y, Nakajima K, Koh M, Nishigaki T, Saito T, Yamamoto K, Yamashita K, Tanaka K, Makino T, Motoori M, Omori T, Hirota S , Hayashi Y, Takehara T, Eguchi H, Doki Y.	Plasma trough concentration of imatinib and its effect on therapeutic efficacy and adverse events in Japanese patients with GIST.	Int J Clin Oncol.	28	680-687	2023
飯沼 久恵, 松田 圭二, 橋口 陽二郎	消化器がんにおける血漿エクソソーム内包microRNAのバイオマーカーとしての有用性	分子細胞治療フロンティア2020		222-230	2020
橋口 陽二郎 , 小澤 毅士, 端山 軍, 野澤 慶次郎, 松田 圭二	【消化器悪性腫瘍診療におけるガイドラインの功罪】大腸癌診療におけるガイドラインの功罪	臨床雑誌外科	82(6)	623-628	2020
松田 圭二, 橋口 陽二郎 , 端山 軍, 土屋 剛史, 野澤 慶次郎	【消化管症候群(第3版) その他の消化管疾患を含めて】空腸、回腸、盲腸、結腸、直腸(下)	日本臨牀	別冊	311-315	2020

	腸閉塞 腸重積症		候群 (第3 版) IV		
Shinto E, Oki E, Shimokawa M, Yamaguchi S, Ishiguro M, Morita M, Kusumoto T, Tomita N, Hashiguchi Y , Tanaka M, Ohnuma S, Tada S, Matsushima T, Hase K.	A Validation Study for Recurrence Risk Stratification of Stage II Colon Cancer Using the 55-Gene Classifier.	Oncology	98(8)	534-541	2020
Kotaro Hama, Yuko Fujiwara, Tamuro Hayama, Tsuyoshi Ozawa, Keijiro Nozawa, Keiji Matsuda, Yojiro Hashiguchi , Kazuaki Yokoyama	Very long-chain fatty acids are accumulated in triacylglycerol and nonesterified forms in colorectal cancer tissues	Scientific reports	11(1)	6163	2020
Hayama T, Ozawa T, Asako K, Kondo R, Ono K, Okada Y, Tsukamoto M, Fukushima Y, Shimada R, Nozawa K, Matsuda K, Fujii S, Fukagawa T, Hashiguchi Y .	Impact of Colon Cancer Location on the Prognostic Significance of Nutritional Indexes and Inflammatory Markers.	In Vivo	35	1261-1269	2021
Tsuyoshi Ozawa, Yojiro Hashiguchi , Soichiro Ishihara, Tamuro Hayama, Takeshi Tsuchiya, Keijiro Nozawa, Shinichi Yamauchi, Kenichi Sugihara, Keiji Matsuda	Proposal for a post-operative surveillance strategy for stage I colorectal cancer patients based on a novel recurrence risk stratification: a multicenter retrospective study	International Journal of Colorectal Disease	36(1)	67-74	2021
Toru Beppu, Katsunori Imai, Goro Honda, Katsunori Sakamoto, Shin Kobayashi, Itaru Endo, Kiyoshi Hasegawa, Kenjiro Kotake, Michio Itabashi, Yojiro Hashiguchi , Yoshihito Kotera, Tatsuro Yamaguchi, Ken Tabuchi, Hiroto Kobayashi, Kensei Yamaguchi, Satoshi Morita, Ken Kikuchi, Masaru Miyazaki, Kenichi Sugihara, Masakazu Yamamoto, Keiichi Takahashi, Joint Committee for Nationwide Survey on Colorectal Liver Metastasis	Proposal of a novel H category-based classification of colorectal liver metastases based on a Japanese nationwide survey	Journal of hepatobiliary-pancreatic sciences	28(4)	317-326	2021
松田 圭二, 橋口 陽二郎	【消化管診断・治療手技のすべて2021】小腸 診断 小腸の解剖	胃と腸	56(5)	682	2021
Tsuyoshi Ozawa, Keiji Matsuda, Soichiro Ishihara, Yoshihisa Fukushima, Ryu Shimada, Tamuro Hayama, Keijiro Nozawa, Yojiro Hashiguchi	The robust performance of carcinoembryonic antigen levels after adjuvant chemotherapy for the recurrence risk stratification in patients with colorectal cancer	Journal of surgical oncology	124(1)	97-105	2021
橋口陽二郎 , 松田圭二, 野澤 慶次郎, 端山 軍, 島田 竜, 金子 建介, 福島 慶久, 大野 航平, 浅古 謙太郎, 岡田 有加, 宮田 敏弥, 岡 志郎, 田中 信治	【原発性小腸癌-見えてきたその全貌】原発性小腸癌の外科手術現状と問題点	胃と腸 (0536-2180)	57(6)	803-809	2022
Shun Ishiyama, Takeshi Yamada, Masato Nakamura, Masanobu Enomoto, Kiichi Sugimoto, Hajime Yokomizo,	Efficacy and safety of regorafenib dose-escalation therapy for Japanese patients with refractory metastatic	International Journal of Clinical	27(8)	1300-1308	2022

Chihiro Kosugi, Ryo Ohta, Kei Ishimaru, Hiromichi Sonoda, Keiichiro Ishibashi, Hidekazu Kuramochi, Yoichiro Yoshida, Daisuke Ichikawa, Keiji Hirata, Hiroshi Yoshida, Yojiro Hashiguchi , Hideyuki Ishida, Keiji Koda, Kenji Katsumata, Kazuhiro Sakamoto	colorectal cancer (RECC study)	Oncology			
松田 圭二, 橋口 陽二郎 , 宮田 敏 弥, 浅古 謙太郎, 福島 慶久, 金子 建介, 島田 竜, 端山 軍, 野澤 慶次 郎	【術前画像の読み解きガイド-的 確な術式選択と解剖把握のため に】小腸・大腸 良性疾患 潰瘍 性大腸炎 術式選択のポイント 解剖把握と術中所見	臨床外科	77 (11)	125- 129	2022
Katsunori Sakamoto, Goro Honda, Toru Beppu, Kenjiro Kotake, Masakazu Yamamoto, Keiichi Takahashi, Itaru	Comprehensive data of 4,502 patients newly diagnosed with colorectal liver metastasis between 2015 and 2017, and prognostic data of 2,427 patients newly diagnosed with colorectal liver metastasis in 2013 and 2014: Third report of a nationwide survey in Japan.	Journal of hepato- biliary- pancreatic sciences.			2022
Toru Beppu, Kensuke Yamamura, Katsunori Sakamoto2, Goro Honda, Shin Kobayashi, Itaru Endo, Kiyoshi Hasegawa, Kenjiro Kotake, Michio Itabashi, Yojiro Hashiguchi , Yoshihito Kotera, Tatsuro Yamaguchi, Soichiro Natsume, Ken Tabuchi, Hirotochi Kobayashi, Kensei Yamaguchi, Satoshi Morita, Ken Kikuchi, Masaru Miyazaki, Kenichi Sugihara, Masakazu Yamamoto, Keiichi Takahashi	Validation study of the <scp>JSHBPS</scp> nomogram for patients with colorectal liver metastases who underwent hepatic resection in the recent era - a nationwide survey in Japan	Hepato- Biliary- Pancreatic Sciences			2022
Yoshida M, Yabuuchi Y, Kakushima N, Kato M, Iguchi M, Yamamoto Y, Kanetaka K, Uraoka T, Fujishiro M, Sho M ; Japan Duodenal Cancer Guideline Committee.	The incidence of non-ampullary duodenal cancer in Japan: The first analysis of a national cancer registry.	J Gastroentero l Hepatol.	In press	In press	2020
Burasakarn P, Higuchi R, Nunobe S, Kanaji S, Eguchi H, Okada KI, Fujii T, Nagakawa Y, Kanetaka K, Yamashita H, Yamada S, Kuroda S, Aoyama T, Akahori T, Nakagawa K, Yamamoto M, Yamaue H, Sho M , Kodera Y; Japan Duodenal Cancer Guideline Committee.	Limited resection vs. pancreaticoduodenectomy for primary duodenal adenocarcinoma: a systematic review and meta- analysis	J Clin Oncol.	Mar 26(3)	450- 460	2021
Tsutsumi K, Kato M, Kakushima N, Iguchi M, Yamamoto Y, Kanetaka K, Uraoka T, Fujishiro M, Sho M ; Japan Duodenal Cancer Guideline Committee.	Efficacy of endoscopic preventive procedures to reduce delayed adverse events after endoscopic resection of superficial nonampullary duodenal epithelial tumors: a meta-analysis of observational comparative trials.	Gastrointest Endosc	Feb 93(2)	367- 374	2021
Nakagawa K, Sho M , Okada KI, Akahori T, Aoyama T, Eguchi H, Fujii T, Higuchi R, Kanaji S, Kanetaka K,	Surgical results of non-ampullary duodenal cancer: a nationwide survey in Japan.	J Gastroentero l.	Feb;5 7(2)	70-81	2022

Kuroda S, Nagakawa Y, Nunobe S, Yamada S, Yamashita H, Yamaue H, Kodera Y; Japan Duodenal Cancer Guideline Committee.					
<u>庄 雅之</u> , 中川 顕志, 赤堀 宇広	【非乳頭部十二指腸腫瘍診療の進歩】十二指腸癌診療ガイドラインの概要	日本消化器病学会雑誌	119巻2号	95-102	2022
<u>庄 雅之</u> , 中川 顕志, 赤堀 宇広	FOCUS「十二指腸癌診療ガイドライン」の要点 特に外科治療に関して	臨床外科	77巻2号	220-223	
Nakagawa K, <u>Sho M</u> , Fujishiro M, Kakushima N, Horimatsu T, Okada KI, Iguchi M, Uraoka T, Kato M, Yamamoto Y, Aoyama T, Akahori T, Eguchi H, Kanaji S, Kanetaka K, Kuroda S, Nagakawa Y, Nunobe S, Higuchi R, Fujii T, Yamashita H, Yamada S, Narita Y, Honma Y, Muro K, Ushiku T, Ejima Y, Yamaue H, Kodera Y.	Clinical practice guidelines for duodenal cancer 2021	J Gastroenterol.	Dec;57(12)	927-941	2022
Yabuuchi Y, Yoshida M, Kakushima N, Kato M, Iguchi M, Yamamoto Y, Kanetaka K, Uraoka T, Fujishiro M, <u>Sho M</u>	Risk Factors for Non-Ampullary Duodenal Adenocarcinoma: A Systematic Review	Dig Dis.	40(2)	147-155	2022
Saito Y, Hayashi R, Iida Y, Mizumachi T, Fujii T, Matsumoto F, Beppu T, Yoshida M, Shinomiya H, Kamiyama R, Kitano M, Yokoshima K, Fujimoto Y, Hama T, Yamashita T, Okami K, Miura K, Fujisawa T, Sano D, Kato H, Minami S, Sugawara M, Masuda M, Ota I, Iwae S, Kawata R, Monden N, Imai T, Asakage T, Okada M, Yoshikawa T, Tanioka K, Kitayama M, Doi M, Fujii S, Fujii M, Oridate N, Nakamizo M, Yoshimoto S, <u>Homma A</u> , Nibu KI, Yane K.	Optimization of therapeutic strategy for p16-positive oropharyngeal squamous cell carcinoma: Multi-institutional observational study based on the national Head and Neck Cancer Registry of Japan.	Cancer	126	4177-4187	2020
Shiga K, Nibu KI, Fujimoto Y, Asakage T, <u>Homma A</u> , Mitani H, Ogawa T, Okami K, Muro S, Hirano S, Ueda T, Hanai N, Tsukahara K, Ota I, Yoshimoto S, Shinozaki T, Iwae S, Katagiri K, Saito D, Kiyota N, Tahara M, Takahashi F, Hayashi R.	Multi-institutional Survey of Squamous Cell Carcinoma of the External Auditory Canal in Japan.	Laryngoscope.	131	E870-E874	2021
Hasegawa Y, Tsukahara K, Yoshimoto S, Miura K, Yokoyama J, Hirano S, Uemura H, Sugawara M, Yoshizaki T, <u>Homma A</u> , Chikamatsu K, Suzuki M, Shiotani A, Matsuzuka T, Kohno N, Miyazaki M, Oze I, Matsuo K, Kosuda S, Yatabe Y; HNCMM Research Group.	Neck Dissections Based on Sentinel Lymph Node Navigation Versus Elective Neck Dissections in Early Oral Cancers: A Randomized, Multicenter, and Noninferiority Trial.	J Clin Oncol	39(18)	2025-2036	2021
Ronen O, Robbins KT, de Bree R, Guntinas-ichius O, Hartl DM, <u>Homma</u>	Standardization for oncologic head and neck surgery.	Eur Arch Otorhinolar	278(12)	4663-4669	2021

A , Khafif A, Kowalski LP, López F, Mäkitie AA, Ng WT, Rinaldo A, Rodrigo JP, Sanabria A, Ferlito A.		yngol			
Okano S, Homma A , Kiyota N, Tahara M, Hanai N, Asakage T, Matsuura K, Ogawa T, Saito Y, Sano D, Kodaira T, Motegi A, Yasuda K, Takahashi S, Tanaka K, Onoe T, Yokota T, Imamura Y, Ariizumi Y, Akimoto T, Hayashi R.	Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck.	Jpn J Clin Oncol	51(2)	173-179	2021
Homma A , Nakamaru Y, Lund VJ, Hanna EY, Kowalski LP, Toledo RN, Mäkitie AA, Rodrigo JP, Rinaldo A, Snyderman CH, Ferlito A	Endonasal endoscopic surgery for sinonasal squamous cell carcinoma from an oncological perspective.	Auris Nasus Larynx	48(1)	41-49	2021
Shiga K, Nibu KI, Fujimoto Y, Asakage T, Homma A , Mitani H, Ogawa T, Okami K, Murono S, Hirano S, Ueda T, Hanai N, Tsukahara K, Ota I, Yoshimoto S, Shinozaki T, Iwae S, Katagiri K, Saito D, Kiyota N, Tahara M, Takahashi F, Hayashi R.	Multi-institutional Survey of Squamous Cell Carcinoma of the External Auditory Canal in Japan.	Laryngoscope	131(3)	E870-E874	2021
Taguchi J, Shimizu Y, Ariga S, Goda T, Ohhara Y, Honma R, Noguchi T, Takeuchi S, Kinoshita I, Amano T, Mizumachi T, Kano S, Takahara M, Abe T, Homma A , Dosaka-Akita H.	Phase II trial of combination treatment with S-1/cetuximab in patients with platinum-ineligible recurrent and/or metastatic squamous cell carcinoma of the head and neck.	Int J Clin Oncol	26(1)	51-58	2021
Imamura Y, Kiyota N, Tahara M, Hanai N, Asakage T, Matsuura K, Ota I, Saito Y, Sano D, Kodaira T, Motegi A, Yasuda K, Takahashi S, Yokota T, Okano S, Tanaka K, Onoe T, Ariizumi Y, Homma A	Systemic therapy for salivary gland malignancy: current status and future perspectives.	Jpn J Clin Oncol	52(4)	293-302	2022
Ishi Y, Yamaguchi S, Hatanaka KC, Takakuwa E, Motegi H, Honda T, Kobayashi H, Terasaka S, Homma A , Fujimura M, Houkin K.	Cystic Intracranial Recurrence of Olfactory Neuroblastoma without Accumulation on Fluorine-18-fluorodeoxyglucose Positron Emission Tomography.	Acta Med Okayama	76(1)	93-98	2022
Mäkitie AA, Alabi RO, Orell H, Youssef O, Almangush A, Homma A , Takes RP, López F, de Bree R, Rodrigo JP, Ferlito A	Managing Cachexia in Head and Neck Cancer: a Systematic Scoping Review.	Adv Ther	39(4)	1502-1523	2022
本間明宏	ここが変わった！頭頸部癌診療ガイドライン改訂のポイントと2022年版の特徴	耳鼻咽喉科・頭頸部外科	94(11)	902-904	2022
Yoshino T , Pentheroudakis G, Mishima S, Overman MJ, Yeh KH, Baba E, Naito Y, Calvo F, Saxena A, Chen LT, Takeda M, Cervantes A, Taniguchi H, Yoshida K, Kodaera Y, Kitagawa Y, Taberero J, Burris H, Douillard JY	JSCO/ESMO/ASCO/JSMO/TOS: International expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions.	Ann Oncol	Jul;31(7)	861-872	2020

Nio K, Tsuchihashi K, Taguchi K, Yoshihiro T, Yamaguchi K, Ito M, Moriyama S, Fukata M, Fujiwara T, Setsu N, Endo M, Matsumoto Y, Wakasaki T, Yasumatsu R, Ariyama H, Kusaba H, Kishimoto J, Akashi K, <u>Baba E</u>	Exploratory retrospective study of risk factors for thromboembolism treated with multi-kinase inhibitor pazopanib or lenvatinib	Int J Surg Oncol	5	e89	2020
Sakai D, Taniguchi H, Sugimoto N, Tamura T, Nishina T, Hara H, Esaki T, Denda T, Sakamoto T, Okuda H, Satoh T, Tsushima T, Makiyama A, Tsuda T, Hosokawa A, Kuramochi H, Tokunaga S, Moriwaki T, Yasui H, Ishida H, Tsuji A, Otsu S, Shimokawa H, <u>Baba E</u> , Sato M, Matsumoto S, Ozaki Y, Shinozaki K, Tamagawa H, Goto M, Kadowaki S, Fujii H, Koh Y, Yamazaki K, Hironaka S, Kishimoto J, Boku N, Hyodo I, Muro K:	Randomized phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan, and oxaliplatin (WJOG 6510G)	Eur J Cancer.	135	11-21	2020
Tsuruta N, Tsuchihashi K, Ohmura H, Yamaguchi K, Ito M, Ariyama H, Kusaba H, Akashi K, <u>Baba E</u> :	RNA N6-methyladenosine demethylase FTO regulates PD-L1 expression in colon cancer cells.	Biochem Biophys Res Commun.	530 (1)	235-239	2020
Nishikawa K, Hironaka S, Inagaki T, Komori A, Otsu S, Mitsugi K, Makiyama A, Watanabe K, Tamura S, Okumura Y, Kusaba H, Esaki T, <u>Baba E</u> , Shirao K	A multicentre retrospective study comparing site-specific treatment with empiric treatment for unfavourable subset of cancer of unknown primary site.	Jpn J Clin Oncol	52	1416-1622	2022